Abstract: A method of evaluating fatty liver related disease includes (I) an obtaining step of obtaining amino acid concentration data on a concentration value of an amino acid in blood collected from a subject to be evaluated and (II) a concentration value criterion evaluating step of evaluating a state of a fatty liver related disease including at least one of fatty liver, NAFLD, and NASH in the subject, based on the amino acid concentration data of the subject obtained at the obtaining step.

Abstract: A method of evaluating fatty liver related disease includes (I) an obtaining step of obtaining amino acid concentration data on a concentration value of an amino acid in blood collected from a subject to be evaluated and (II) a concentration value criterion evaluating step of evaluating a state of a fatty liver related disease including at least one of fatty liver, NAFLD, and NASH in the subject, based on the amino acid concentration data of the subject obtained at the obtaining step.

Abstract: An information processing apparatus includes an generating section that generates authentication operation data from an input type associated with the type of the appliance in appliance data and stores the authentication operation data in a storage device, an transmitting section that transmits the authentication operation data to a gateway apparatus, an acquiring section that receives, from the gateway apparatus, input operation data input from an input device of an appliance and stores the input operation data in the storage device, and an collating section that compares the authentication operation data and the input operation data, determines whether the authentication operation data and the input operation data coincide with each other, and outputs collation result data. If the coincidence is determined, the information processing apparatus causes the gateway apparatus to authenticate communication for controlling the appliance between the appliance and the gateway apparatus.

Abstract: In a hepatic disease-evaluating apparatus, an indicator calculating unit calculates an index indicating the degree of hepatic fibrosis from amino acid concentration data to be evaluated including amino acid concentration value, based on one or more indices of fractional expression having amino acid concentration as variable. A disease state evaluating unit evaluates the disease state of the hepatic disease to be evaluated, based on the index value.

Abstract: In a hepatic disease-evaluating apparatus, an indicator calculating unit calculates an index indicating the degree of hepatic fibrosis from amino acid concentration data to be evaluated including amino acid concentration value, based on one or more indices of fractional expression having amino acid concentration as variable. A disease state evaluating unit evaluates the disease state of the hepatic disease to be evaluated, based on the index value.

Abstract: The present invention provides a novel compound having a kininogenase-inhibitory action and its pharmaceutical use. The compounds are represented by the formulas (A), (B), (C), (E) and (H): wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof.

Abstract: An object is to provide a biological state-evaluating apparatus, a biological state-evaluating method, a biological state-evaluating system, a biological state-evaluating program, and a recording medium that can evaluate a biological state with high accuracy by using the concentrations of amino acids in blood. According to the present invention, a Bayesian network method is performed by using previously obtained amino acid concentration data on the concentration values of amino acids and previously obtained biological state data on the numerical value indicative of the biological state so that a Bayesian network model that includes, as explanatory variables, the concentration values of amino acids and the numerical value indicative of the biological state is created, and the biological state of the subject is evaluated by using the created Bayesian network model and the previously obtained amino acid concentration data on the subject.

Abstract: According to the method of evaluating IGT of the present invention, amino acid concentration data on concentration values of amino acids in blood collected from a subject to be evaluated is measured, and an impaired glucose tolerance state in the subject is evaluated based on the measured amino acid concentration data of the subject.

Abstract: A light-emitting device with a protection layer for Zn inter-diffusion and a process to form the device are described. The device of the invention provides an active layer containing aluminum (Al) as a group III element, typically AlGaInAs, and protection layers containing silicon (Si) to prevent the inter-diffusion of zing (Zn) atoms contained in p-type layers surrounding the active layer. One of protection layers is put between the active layer and the p-type cladding layer, while, the other of protection layers is disposed between the active layer and the p-type burying layer.

Abstract: Provided is an apparatus 1 for measuring pressure loss in a filter 2, which apparatus includes filter holding means 3; fluid passing means; flow rate measuring means; pressure loss measuring means; and a flow path 6 which connects the four means such that a fluid can pass between the means. The apparatus further includes flow rate regulating means having a mainstream path 7; a tributary path 8 which is branched from the mainstream path 7 and communicates with the outside; and one or more flow path opening/closing members 9 capable of, in conjunction with the level of the fluid flow rate as measured through the flow rate measuring means, opening or closing the mainstream path 7 or the tributary path 8 such that the flow path opening ratio of each of the paths varies continuously or intermittently. The apparatus achieves reliable and convenient measurement of pressure loss with the flow rate of the fluid which passes through the filter 2 being maintained at a constant level by the flow rate regulating means.

Abstract: According to the method of evaluating metabolic syndrome, amino acid concentration data on the concentration value of amino acid in blood collected from a subject to be evaluated is measured, and the state of metabolic syndrome in the subject is evaluated based on the measured amino acid concentration data of the subject.

Abstract: A light-emitting device with a protection layer for Zn inter-diffusion and a process to form the device are described. The device of the invention provides an active layer containing aluminum (Al) as a group III element, typically AlGaInAs, and protection layers containing silicon (Si) to prevent the inter-diffusion of zing (Zn) atoms contained in p-type layers surrounding the active layer. One of protection layers is put between the active layer and the p-type cladding layer, while, the other of protection layers is disposed between the active layer and the p-type burying layer.

Abstract: A cement admixture of a low environmental load type, capable of reducing hexavalent chromium, having a small slump loss or heat of hydration, hardly neutralized and capable of suppressing autogenous shrinkage to a low level; a cement composition; and cement concrete employing it, are presented. The cement admixture comprises a slowly cooled slag powder which contains melilite as the main component and which has a carbon dioxide absorption of at least 2%, has a CO2 absorption of at least 2%, has a loss on ignition of at most 5%, contains at least 0.5% of sulfur present as non-sulfuric acid form sulfur and/or has a concentration of non-sulfuric acid form sulfur to elute, of at least 100 mg/l, and further, preferably, has a degree of vitrification of at most 30%, a melilite lattice constant a of from 7.73 to 7.82 and/or a Blaine specific surface area of at least 4,000 cm2/g.

Abstract: A light-emitting device and a method to from the device are is described. The device described herein may realize the transversely single mode operation by the buried mesa configuration even when the active layer contains aluminum. The method provides a step to form the mesa on a semiconductor substrate with an average dislocation density of 500 to 5000 cm?2, a step to form a protection layer, which prevents the active layer from oxidizing, at least on a side of the active layer, and a step to from a blocking layer so as to cover the protection layer and to bury the mesa.

Abstract: Amino acids other than glutamic acid are used as a metabotropic glutamate receptor activator. More preferably, aspartic acid, valine and cysteine are used as a group I metabotropic glutamate receptor activator; alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine, ornithine, taurine and hydroxyproline are used as a group II metabotropic glutamate receptor activator; and cysteine is used as a group III metabotropic glutamate receptor activator.

Abstract: Benzamidine derivatives of the following formulae or analogs thereof, i.e., pharmaceutically acceptable salts thereof, are provided.

Abstract: In a hepatic disease-evaluating apparatus, an indicator calculating unit calculates an index indicating the degree of hepatic fibrosis from amino acid concentration data to be evaluated including amino acid concentration value, based on one or more indices of fractional expression having amino acid concentration as variable. A disease state evaluating unit evaluates the disease state of the hepatic disease to be evaluated, based on the index value.

Abstract: The present invention is to provide a vertical cavity surface emitting laser diode (VCSEL) that has a functional distributed Bragg reflector (DBR) comprised of less number of pairs of reflective layers. The VCSEL of the invention include a lower DBR, an upper DBR and an active layer arranged between the upper and lower DBRs. The upper DBR is comprised of a plurality of pairs including GaAs layers and aluminum oxide layers, thus the GaAs layers and the aluminum oxide layers are alternately stacked to each other. Since the refractive index of the aluminum oxide (Al2O3) is 1.67 at 1.3 ?m and that of the GaAs is 3.51, the difference of these refractive index becomes 1.85, which is far greater than the combination of the AlAs and the GaAs, thereby decreasing the number of pairs for the DBR.

Abstract: Provided is an apparatus 1 for measuring pressure loss in a filter 2, which apparatus includes filter holding means 3; fluid passing means; flow rate measuring means; pressure loss measuring means; and a flow path 6 which connects the four means such that a fluid can pass between the means. The apparatus further includes flow rate regulating means having a mainstream path 7; a tributary path 8 which is branched from the mainstream path 7 and communicates with the outside; and one or more flow path opening/closing members 9 capable of, in conjunction with the level of the fluid flow rate as measured through the flow rate measuring means, opening or closing the mainstream path 7 or the tributary path 8 such that the flow path opening ratio of each of the paths varies continuously or intermittently. The apparatus achieves reliable and convenient measurement of pressure loss with the flow rate of the fluid which passes through the filter 2 being maintained at a constant level by the flow rate regulating means.

Abstract: The present invention provides a novel compound having a kininogenase-inhibitory action and its pharmaceutical use. The compounds are represented by the formulas (A), (B), (C), (E) and (H): wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof.